Original articleSimultaneous determination of naltrexone and bupropion in their co-formulated tablet utilizing green chromatographic approach with application to human urine
-
Add time:09/25/2019 Source:sciencedirect.com
A rapid, simple and accurate micellar HPLC-method was adopted and validated for concurrent quantification of naltrexone hydrochloride (NTX) and bupropion hydrochloride (BUP). The proposed method was conducted on RP-18 LiChrosorb® column (150 mm × 4.6 mm i.d. 5-µm particle size) at 25 °C, as a stationary phase and a mixture of 0.175 M sodium dodecyl sulphate (SDS), 0.3% triethanolamine (TEA) and 12% n-propanol in 0.02 M ortho (o)-phosphoric acid of pH 3.5 as a developing system. It was pumped at a flow rate of 1.2 mL/min, with ultraviolet detection at 210 nm. The linearity ranges were 0.5–15.0 µg/mL and 1.2–18.0 µg/mL, with detection limits of 0.10 and 0.31 µg/mL and quantification limits of 0.30 and 0.93 µg/mL for NTX and BUP, respectively. The studied drugs were successfully quantified by applying the proposed method in their co-formulated tablet. The cited method was also applied for in-vitro quantification of BUP in spiked human urine without prior extraction.
We also recommend Trading Suppliers and Manufacturers of Naltrexone hydrochloride (cas 16676-29-2). Pls Click Website Link as below: cas 16676-29-2 suppliers
Prev:Research ArticlesStructural characterization of anhydrous naloxone‐ and Naltrexone hydrochloride (cas 16676-29-2) by high resolution laboratory X‐ray powder diffraction and thermal analysis
Next:Sex differences in the effect of bupropion and naltrexone combination on alcohol drinking in mice) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Design of controlled release inert matrices of Naltrexone hydrochloride (cas 16676-29-2) based on percolation concepts09/27/2019
- Sex differences in the effect of bupropion and naltrexone combination on alcohol drinking in mice09/26/2019
- Research ArticlesStructural characterization of anhydrous naloxone‐ and Naltrexone hydrochloride (cas 16676-29-2) by high resolution laboratory X‐ray powder diffraction and thermal analysis09/24/2019
- Niosomes and discomes for ocular delivery of Naltrexone hydrochloride (cas 16676-29-2): Morphological, rheological, spreading properties and photo-protective effects09/10/2019
- Novel in situ gelling ocular films for the opioid growth factor-receptor antagonist-Naltrexone hydrochloride (cas 16676-29-2): Fabrication, mechanical properties, mucoadhesion, tolerability and stability studies09/09/2019
- Hydrogels for diabetic eyes: Naltrexone loading, release profiles and cornea penetration09/08/2019
- Pharmaceutics, Preformulation and Drug DeliveryDesign and Evaluation of Controlled-Release Niosomes and Discomes for Naltrexone hydrochloride (cas 16676-29-2) Ocular Delivery09/07/2019
- In-vivo study of Naltrexone hydrochloride (cas 16676-29-2) release from an in-situ forming PLGA-PEG-PLGA system in the rabbit09/06/2019
-
Health and Chemical more >


